Drug Trial Radar · NCT04117607
Safety and Pharmacokinetics of Rezafungin
Last checked: Nov 19, 2026Latest source record: Jul 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Dec 4, 2019
Primary completion
May 11, 2020
Study completion May 11, 2020
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in six cohorts receiving a single subcutaneous (SC) dose of 1, 10, 30, 60, 100, or 200 mg of rezafungin; a multiple ascending dose (MAD) study in four cohorts receiving 30 mg x 3 doses, 60 mg x 3 doses, 100 mg x 3 doses, or 200 mg x 3 doses of rezafungin SC with dosing frequency of once every 7 days; and a two-period cross-over bioavailability (BA) study receiving 100 mg of rezafungin. The two period cross-over BA study will be assessed unblinded in two sequences (10 subjects, 100 mg or maximum tolerated dose (MTD) of rezafungin in Part 1); 5 subjects will receive an SC injection of rezafungin in Period 1 followed by an intravenous (IV) infusion of rezafungin in Period 2, and 5 subjects will receive an IV infusion of rezafungin in Period 1 followed by an SC injection of rezafungin in Period 2. Each SAD (except cohort 1) and MAD cohort will contain 8 subjects (6 subjects will receive a SC injection of rezafungin and 2 subjects will receive placebo). Each SAD (except cohort 1) and MAD cohort will be conducted with sentinel dosing. SAD cohort 1 will be comprised of 4 subjects (3:1 rezafungin to placebo) with no sentinel dosing. Parts 2 and 3 of the study will only be conducted after FDA review for safety data and PK data from all subjects participating in Part 1; Part 3 may be run in parallel with the first cohort (Cohort 7) of Part 2. Individuals in the SAD cohorts will participate for approximately 58 days, including up to 28 days for screening and 30 days for dosing and follow-up (FU). Individuals in the MAD cohorts will participate for approximately 73 days, including up to 28 days for screening and 45 days for dosing and FU. Individuals in the BA cohorts will participate for approximately 80 days, including up to 28 days for screening and 52 days for dosing and FU. The study will have a duration of approximately 30 months. The primary objectives are to determine the: 1) safety and tolerability of single ascending SC doses (SAD) of rezafungin; 2) safety and tolerability of multiple ascending SC doses (MAD) of rezafungin; and 3) pharmacokinetic (PK) profile in plasma of rezafungin in healthy adult subjects.
Conditions
- Fungal Infection
Interventions
PlaceboOther
5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
RezafunginDrug
Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
RezafunginDrug
Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 2Time frame: Day 2
- Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 7Time frame: Day 7
- Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 30Time frame: Day 30
- Number of Participants With Abnormal Chemistry Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
- Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 2Time frame: Day 2
- Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 7Time frame: Day 7
- Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Single Ascending Dose (SAD) on Day 30Time frame: Day 30
- Number of Participants With Abnormal Hematology Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
- Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 2Time frame: Day 2
- Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
- Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
- Number of Participants With Abnormal Coagulation Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
- Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 2Time frame: Day 2
- Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
- Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
- Number of Participants With Abnormal Urinalysis Laboratory Toxicity Results for Multiple Ascending Dose (MAD)Time frame: Day 2 through Day 45
- Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 1Time frame: Day 1
- Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 7Time frame: Day 7
- Number of Participants With Abnormal ECG Toxicity Results for Single Ascending Dose (SAD), Day 30Time frame: Day 30
- Number of Participants With Abnormal ECG Toxicity Results for Multiple Ascending Doses (MAD)Time frame: Day 1 through Day 45
- Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 1Time frame: Day 1
- Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 2Time frame: Day 2
- Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 4Time frame: Day 4
- Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 7Time frame: Day 7
- Number of Participants With Abnormal Physical Exams for Single Ascending Dose (SAD), Day 30Time frame: Day 30
- Number of Participants With Abnormal Physical Exams for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 15 Minutes Post-doseTime frame: Day 1, 15 minutes post-dose
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 1 Hour Post-doseTime frame: Day 1, 1 hour post-dose
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 1, 2 Hours Post-doseTime frame: Day 1, 2 hours post-dose
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 2Time frame: Day 2
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 4Time frame: Day 4
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 7Time frame: Day 7
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 14Time frame: Day 14
- Number of Participants With Abnormal Vital Signs for Single Ascending Dose (SAD), Day 30Time frame: Day 30
- Number of Participants With Abnormal Vital Signs for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Number of Participants With Unsolicited Adverse Events (AEs) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30.
- Number of Participants With Unsolicited Adverse Events (AEs) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Number of Unsolicited Adverse Events Reported for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30.
- Number of Unsolicited Adverse Events Reported for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Number of Participants With at Least One Severe Adverse Event (SAE) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30
- Number of Participants With at Least One Severe Adverse Event (SAE) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Number of Participants With Solicited Local Reactogenicity Symptom(s) for Single Ascending Dose (SAD)Time frame: Day 1 through Day 30
- Number of Participants With Solicited Local Reactogenicity Symptom(s) for Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Rezafungin Concentrations in Plasma, SAD 10 mg Dose Group Concentrations of Rezafungin in Plasma SamplesTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameter (Cmax) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameters (Tmax and t 1/2) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameters (AUC 0-last and AUC 0-inf ) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameter (Lambda z) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameter (CL/F) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin PK Parameter (Vz/F) in Plasma, SAD 10 mg Dose GroupTime frame: 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 96 h, 144 h, 312 h, and 696 h post-dose
- Rezafungin Concentrations in Plasma Samples, Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
- Rezafungin PK Parameters in Plasma, Multiple Ascending Dose (MAD)Time frame: Day 1 through Day 45
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Early Phase Services Clinical Research Unit
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.